Should we interfere with the interleukin-6 receptor during COVID-19 : What do we know?
Copyright © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved..
COVID-19 is a viral infection with predominant respiratory tropism. In its most severe forms, the initial viral aggression leads to acute respiratory failure due to damage secondary to an exacerbated inflammatory response provoked by the activation of innate, followed by adaptive immunity. The inflammatory response may entail respiratory distress syndrome, if not multivisceral failure and death. IL-6 receptor inhibitors (Tocilizumab and Sarilumab) have been proposed as treatments. Numerous studies have provided new information, which remains heterogeneous and difficult to interpret. This review is aimed at clarifying the potential role of IL-6 receptor inhibitors in severe forms of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 40(2023), 1 vom: 26. Jan., Seite 24-37 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ? |
|---|
| Beteiligte Personen: |
Lefèvre, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID 19 |
|---|
| Anmerkungen: |
Date Completed 17.01.2023 Date Revised 03.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2022.11.085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350889880 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350889880 | ||
| 003 | DE-627 | ||
| 005 | 20231226050021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2022.11.085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350889880 | ||
| 035 | |a (NLM)36577608 | ||
| 035 | |a (PII)S0761-8425(22)00460-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lefèvre, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Should we interfere with the interleukin-6 receptor during COVID-19 |b What do we know? |
| 246 | 3 | 3 | |a Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2023 | ||
| 500 | |a Date Revised 03.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a COVID-19 is a viral infection with predominant respiratory tropism. In its most severe forms, the initial viral aggression leads to acute respiratory failure due to damage secondary to an exacerbated inflammatory response provoked by the activation of innate, followed by adaptive immunity. The inflammatory response may entail respiratory distress syndrome, if not multivisceral failure and death. IL-6 receptor inhibitors (Tocilizumab and Sarilumab) have been proposed as treatments. Numerous studies have provided new information, which remains heterogeneous and difficult to interpret. This review is aimed at clarifying the potential role of IL-6 receptor inhibitors in severe forms of COVID-19 | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID 19 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a CortIcosteroid | |
| 650 | 4 | |a Corticoïdes | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a Interleukine 6 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Mortalité | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 700 | 1 | |a Plocque, A |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, M |e verfasserin |4 aut | |
| 700 | 1 | |a Creux, M |e verfasserin |4 aut | |
| 700 | 1 | |a Philippart, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 40(2023), 1 vom: 26. Jan., Seite 24-37 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:1 |g day:26 |g month:01 |g pages:24-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2022.11.085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 1 |b 26 |c 01 |h 24-37 | ||